Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Molecular Devices Introduces FLIPR Calcium 6 Assay Kits

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
Latest addition to the FLIPR Calcium range featuring exclusive fluorophore for assaying the most challenging, low-responding targets.

Molecular Devices announced today the launch of FLIPR® Calcium 6 Assay Kits, the latest addition to their extensive range of calcium assay kits to address diversified GPCR and ion channel targets. Featuring a proprietary fluorophore, the dye offers the highest quantum yield of any calcium indicator on the market, delivering the greatest signal window available in a calcium assay kit. This substantial increase in signal enables researchers to monitor low-responders, including biorelevant reactions from endogenous, primary or stem cell targets.

FLIPR 6 Calcium Assay Kits provide a comprehensive method for detecting intracellular calcium changes in a simple and reliable homogeneous assay format. Combining the novel fluorophore with proven proprietary quench technology, the new assay affords the highest signal to background ratio. The unique dye is more resistant to anion-exchange proteins, enabling measurement with minimal to no probenecid, an exchange inhibitor, when studying cell lines containing an organic anion transporter.

Using a quench-free protocol, the FLIPR Calcium 6-QF Formulation allows assay performance without a masking technology, making it an ideal choice for quench-sensitive applications such as targets sensitive to quenchers or multiplexing with luminescent indicators. The new kits support GPCR targets that can be run on Molecular Devices’ FLIPR® Tetra and FlexStation® 3 Instrumentation.

Klaus Lun, Vice President of Product Marketing at Molecular Devices commented: “We are committed to providing a strong product pipeline, not only in instrumentation but also in reagents. The introduction of the new FLIPR 6 Calcium Assay Kits opens the door for researchers to assay the low-responding and more challenging targets.  As we continue to move forward our goal is to enable researchers to screen more biorelevant assays and to further explore new assay dynamics including beat rate for cardiotoxicity studies. ”

Please visit www.moleculardevices.com/FLIPR_Calcium6 for more details and to request an evaluation sample.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Molecular Devices Partners with Roche
Partnership will develop custom Ruthenium Nano-TRF Detection Platform.
Thursday, November 06, 2014
Molecular Devices Becomes Global Distributor of IonFlux
Molecular Devices makes deal with Fluxion Biosciences to distribute their automated electrophysiology systems and associated products.
Tuesday, May 28, 2013
Molecular Devices Forms Scientific Advisory Board
Multidisciplinary team will guide product and application development to deliver maximum value to customers.
Thursday, December 27, 2012
Molecular Devices to attend ADME & Predictive Toxicology Europe
Company is to showcase its SpectraMax® Paradigm® microplate reader during the European conference in Munich, Germany, 13-14 March 2012.
Wednesday, February 29, 2012
Molecular Devices Awarded Patent for Population Patch Clamp Recording Technique
The parallel recording technique measures ionic currents from a population of cells, rather than single cells, on planar patch clamp systems and enhances ion channel assay success rates to near 100%.
Tuesday, January 10, 2012
Registration opens for RNAi and High Content Imaging 2011
Molecular Devices Inc. announces that they have opened registration for its RNAi & High Content Imaging Symposium 2011, to be held at the Oxford Spires Four Pillars, Oxford on 1st April 2011.
Tuesday, February 08, 2011
Molecular Devices Launches New Products & Customer-Focused Brand at Society for Biomolecular Sciences Meeting
New IonWorks Barracuda™ Automated High-Speed Patch Clamp System & AquaMax® 2000/4000 Microplate Washer 96 Cell-Wash Head
Thursday, April 08, 2010
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!